Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly.
Adriana P KukerWei ShenZhezhen JinSimran SinghJun ChenJeffrey N BrucePamela U FredaPublished in: Journal of the Endocrine Society (2021)
Long-term pegvisomant therapy is accompanied by increases in VAT and SAT mass that do not differ from predicted, stable SM mass and improvements in glucose metabolism. Long-term pegvisomant therapy does not produce a GH deficiency-like pattern of body composition change.